ANTX — AN2 Therapeutics Share News
0.000.00%
Last trade - 00:00Brief: An2 Therapeutics Initiates Pivotal Phase 2/3 Trial Evaluating Epetraborole For Treatment-Refractory Mac Lung Disease
Brief: AN2 Therapeutics Posts Quarterly Loss Per Share $2.98
Biopharmaceutical co AN2 Therapeutics jumps in Nasdaq debut
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
Brief: An2 Therapeutics Inc Announces Pricing Of Its Upsized IPO Of 4,600,000 Shares Of Its Common Stock At A Price To Public Of $15.00/Share